Phase I clinical trial - Phases précoces tumeurs solides

Phases précoces tumeurs solides
Essai clinique fermé
Public cible
A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors.
Description de l'essai

This is a phase I trial with an OX40 agonist alone or in combination with PD1 inhibitor in patients with any kind of cancer.;This open-label, phase I, dose-escalation study will serve to determine the recommended Phase 2 dose (RPTD), the maximum tolerated dose (MTD), and will evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.